Nigel B Jamieson

List of Publications by Year
in descending order

103	12,404	53794	38395
papers	citations	45 h-index	95 g-index

106	106	106	18332
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data. Clinical Cancer Research, 2022, 28, 4056-4069.	7.0	14
2	Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2021, 274, 1051-1057.	4.2	43
3	Biology and Clinical Application of Regulatory RNAs in Hepatocellular Carcinoma. Hepatology, 2021, 73, 38-48.	7.3	20
4	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology, 2021, 160, 362-377.e13.	1.3	90
5	Molecular Subtyping of Pancreatic Cancer. , 2021, , 305-319.		0
6	Immuno-Oncology in Pancreatic Cancer. , 2021, , 287-304.		2
7	DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 2021, 4, 155.	4.4	26
8	Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development. Surgery, 2021, 169, 708-720.	1.9	22
9	Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2021, 47, 2248-2255.	1.0	8
10	Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. European Journal of Surgical Oncology, 2021, 47, 2543-2550.	1.0	8
11	The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis. Surgery, 2021, 170, 1195-1204.	1.9	11
12	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 2021, 12, 6738.	12.8	10
13	ROR1 and ROR2 expression in pancreatic cancer. BMC Cancer, 2021, 21, 1199.	2.6	4
14	RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas. Modern Pathology, 2020, 33, 657-664.	5.5	22
15	PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer. Clinical Oncology, 2020, 32, 1-4.	1.4	23
16	Pancreatic Cancer: From Genome Discovery to PRECISION-Panc. Clinical Oncology, 2020, 32, 5-8.	1.4	15
17	Histopathologic Predictors of Survival and Recurrence in Resected Ampullary Adenocarcinoma. Annals of Surgery, 2020, 272, 1086-1093.	4.2	36
18	Precision Oncology in Surgery. Annals of Surgery, 2020, 272, 366-376.	4.2	48

#	Article	IF	Citations
19	Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors. Frontiers in Medicine, 2020, 7, 385.	2.6	7
20	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Reports, 2020, 31, 107625.	6.4	78
21	Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. Pancreas, 2020, 49, 224-229.	1.1	9
22	Development and external validation of a prediction model for survival in patients with resected ampullary adenocarcinoma. European Journal of Surgical Oncology, 2020, 46, 1717-1726.	1.0	17
23	Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: A systematic review. Clinical Endocrinology, 2020, 92, 396-406.	2.4	51
24	Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. British Journal of Surgery, 2020, 107, 1171-1182.	0.3	34
25	Pancreatoduodenectomy With Arterial Resection for Locally Advanced Pancreatic Cancer of the Head. Pancreas, 2020, 49, 621-628.	1.1	13
26	The integrin Î±vÎ²6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Journal of Pathology, 2019, 249, 332-342.	4.5	66
27	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Journal of the National Cancer Institute, 2019, 111, 782-794.	6.3	223
28	Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. British Journal of Surgery, 2019, 106, 342-354.	0.3	38
29	Management of post-pancreatectomy haemorrhage using resuscitative endovascular balloon occlusion of the aorta. Langenbeck's Archives of Surgery, 2019, 404, 253-255.	1.9	7
30	Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. European Journal of Surgical Oncology, 2019, 45, 218-224.	1.0	22
31	Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal Pancreatectomy. Annals of Surgery, 2019, 269, 143-149.	4.2	142
32	Identification of an Optimal Cut-off for Drain Fluid Amylase on Postoperative Day 1 for Predicting Clinically Relevant Fistula After Distal Pancreatectomy. Annals of Surgery, 2019, 269, 337-343.	4.2	42
33	The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy. Annals of Surgery, 2019, 270, 147-157.	4.2	43
34	Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chinese Clinical Oncology, 2019, 8, 16-16.	1.2	33
35	Observation or resection of pancreatic intraductal papillary mucinous neoplasm: An ongoing tug of war. World Journal of Gastrointestinal Oncology, 2019, 11, 1092-1100.	2.0	12
36	Defining the molecular pathology of pancreatic body and tail adenocarcinoma. British Journal of Surgery, 2018, 105, e183-e191.	0.3	88

#	Article	IF	Citations
37	Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy. Annals of Surgery, 2018, 267, 608-616.	4.2	117
38	Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies. Journal of Gastrointestinal Surgery, 2018, 22, 68-76.	1.7	19
39	Markov decision analysis of neoadjuvant treatment pathway versus surgery first pathway for resectable pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 456-456.	1.6	0
40	Incorporation of Procedure-specific Risk Into the ACS-NSQIP Surgical Risk Calculator Improves the Prediction of Morbidity and Mortality After Pancreatoduodenectomy. Annals of Surgery, 2017, 265, 978-986.	4.2	88
41	Investigating Various Thresholds as Immunohistochemistry Cutoffs for Observer Agreement. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 599-608.	1.2	6
42	Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 2017, 543, 65-71.	27.8	716
43	Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Therapy, 2017, 24, 134-140.	4.6	72
44	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	1.3	174
45	The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 2017, 8, 683-695.	1.4	12
46	Feasibility and clinical utility of EUS guided biopsy of pancreatic cancer for next-generation genomic sequencing.. Journal of Clinical Oncology, 2017, 35, e15755-e15755.	1.6	0
47	Serum amylase and C-reactive protein in risk stratification of pancreas-specific complications after pancreaticoduodenectomy. British Journal of Surgery, 2016, 103, 553-563.	0.3	60
48	A Glasgow Tippleâ€"transjugular intrahepatic portosystemic shunt insertion prior to Whipple resection. Journal of Surgical Case Reports, 2016, 2016, rjw089.	0.4	4
49	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2016, 29, 832-845.	16.8	645
50	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Reports, 2016, 14, 907-919.	6.4	107
51	Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531, 47-52.	27.8	2,700
52	Targeting the <scp>LOX</scp> / <scp>hypoxia</scp> axis reverses many of the features that make pancreatic cancer deadly: inhibition of <scp>LOX</scp> abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 2015, 7, 1063-1076.	6.9	223
53	Routine Drainage After Pancreaticoduodenectomy. Annals of Surgery, 2015, 262, e107.	4.2	1
54	Inflammatory Dysregulation and Cancer: From Molecular Mechanisms to Therapeutic Opportunities. , 2015, , 375-395.		1

#	Article	IF	Citations
55	Ligand-Occupied Integrin Internalization Links Nutrient Signaling to Invasive Migration. Cell Reports, 2015, 10, 398-413.	6.4	101
56	Pancreatic cancer genomics: where can the science take us?. Clinical Genetics, 2015, 88, 213-219.	2.0	13
57	Cyst Fluid Biomarkers for Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Critical Review from the International Expert Meeting on Pancreatic Branch-Duct-Intraductal Papillary Mucinous Neoplasms. Journal of the American College of Surgeons, 2015, 220, 243-253.	0.5	64
58	Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518, 495-501.	27.8	2,132
59	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. European Journal of Cancer, 2015, 51, 1389-1404.	2.8	94
60	Outcome after surgical resection for duodenal adenocarcinoma in the UK. British Journal of Surgery, 2015, 102, 676-681.	0.3	55
61	RE:nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. Journal of the National Cancer Institute, 2015, 107, djv204.	6.3	1
62	Cancer Genetics and Implications for Clinical Management. Surgical Clinics of North America, 2015, 95, 919-934.	1.5	6
63	Influence of IP-10/CXCL10 induction in human pancreatic cancer stroma on lymphocytes recruitment and correlation with survival.. Journal of Clinical Oncology, 2015, 33, 290-290.	1.6	1
64	SIRT3 & SIRT7: Potential Novel Biomarkers for Determining Outcome in Pancreatic Cancer Patients. PLoS ONE, 2015, 10, e0131344.	2.5	51
65	Role of neoadjuvant treatment regimens for locally advanced pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, 444-444.	1.6	0
66	IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget, 2014, 5, 11064-11080.	1.8	103
67	A microRNA meta-signature for pancreatic ductal adenocarcinoma. Expert Review of Molecular Diagnostics, 2014, 14, 267-271.	3.1	29
68	Stratified Medicine for Pancreatic Cancer. , 2014, , 807-814.		0
69	A national survey of attitudes to research in Scottish General Surgery Trainees. Scottish Medical Journal, 2014, 59, 9-15.	1.3	5
70	Investigation and management of pancreatic tumours. Frontline Gastroenterology, 2014, 5, 144-152.	1.8	2
71	Can we move towards personalised pancreatic cancer therapy?. Expert Review of Gastroenterology and Hepatology, 2014, 8, 335-338.	3.0	5
72	Targeting mTOR dependency in pancreatic cancer. Gut, 2014, 63, 1481-1489.	12.1	107

#	Article	IF	Citations
73	Fascin Is Regulated by Slug, Promotes Progression of Pancreatic Cancer in Mice, and Is Associated With Patient Outcomes. Gastroenterology, 2014, 146, 1386-1396.e17.	1.3	100
74	Serum amylase on the night of surgery predicts clinically significant pancreatic fistula after pancreaticoduodenectomy. Hpb, 2014, 16, 610-619.	0.3	67
75	Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clinical Pathology, 2014, 14, 35.	1.8	32
76	AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget, 2014, 5, 6142-6167.	1.8	30
77	Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2013, 17, 887-898.	1.7	80
78	The Prognostic Influence of Resection Margin Clearance Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2013, 17, 511-521.	1.7	80
79	Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. Journal of Clinical Oncology, 2013, 31, 1348-1356.	1.6	142
80	Reply to G.F. Arroyo. Journal of Clinical Oncology, 2013, 31, 3843-3844.	1.6	0
81	Exploiting inflammation for therapeutic gain in pancreatic cancer. British Journal of Cancer, 2013, 108, 997-1003.	6.4	73
82	MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2012, 18, 534-545.	7.0	192
83	The Relationship Between Tumor Inflammatory Cell Infiltrate and Outcome in Patients with Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2012, 19, 3581-3590.	1.5	61
84	Rab25 and CLIC3 Collaborate to Promote Integrin Recycling from Late Endosomes/Lysosomes and Drive Cancer Progression. Developmental Cell, 2012, 22, 131-145.	7.0	275
85	Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis. Molecular Cell, 2011, 42, 36-49.	9.7	179
86	Clinical Potential of MicroRNAs in Pancreatic Ductal Adenocarcinoma. Pancreas, 2011, 40, 1165-1171.	1.1	42
87	The Challenges of Improving Survival Following Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2011, 254, 386.	4.2	0
88	A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2011, 18, 2318-2328.	1.5	104
89	Peripancreatic Fat Invasion Is an Independent Predictor of Poor Outcome Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2011, 15, 512-524.	1.7	25
90	Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. Clinical Cancer Research, 2011, 17, 3316-3331.	7.0	114

#	Article	IF	Citations
91	Positive Mobilization Margins Alone Do Not Influence Survival Following Pancreatico-Duodenectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2010, 251, 1003-1010.	4.2	178
92	Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics, 2010, 11, 532.	2.8	27
93	Drug induced pancreatitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 143-155.	2.4	147
94	Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 246-251.	7.1	530
95	Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2010, 139, 292-303.	1.3	123
96	LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest. Gastroenterology, 2010, 139, 586-597.e6.	1.3	130
97	Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 341-352.	3.8	105
98	Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology, 2006, 6, 450-453.	1.1	147
99	Adiponectin Predicts Insulin Resistance But Not Endothelial Function in Young, Healthy Adolescents. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4615-4621.	3.6	37
100	Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. British Journal of Cancer, 2005, 92, 21-23.	6.4	136
101	Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer. Cytokine, 2004, 27, 90-92.	3.2	46
102	Paradoxical Elevation in Adiponectin Concentrations in Women With Preeclampsia. Hypertension, 2003, 42, 891-894.	2.7	148
103	Comparison of simple acid-ethanol precipitation with gel exclusion chromatography for measuring leptin binding in serum of normal subjects and cancer patients. Annals of Clinical Biochemistry, 2003, 40, 185-187.	1.6	2